结外NK/T细胞淋巴瘤的治疗进展
|
摘要
<正>自然杀伤(NK)/T细胞淋巴瘤(ENKTL)是一类成熟的T细胞和NK细胞淋巴瘤的亚型,以结外受累为特征;发病率低,占恶性淋巴瘤的3%～10%,近年来,其发病率逐渐上升;发病具有明显的地域差别,亚洲及拉丁美洲等地区高发,而欧美国家少见;发病人群以中年为主,且以男性多见~([1-5])。ENKTL 80%发生于鼻腔,病灶常沿中线分布,以血管为中心呈侵袭性
引文
[1] PERRY AM,DIEBOLD J,NATHWANI BN,et al.Non-Hodgkin lymphoma in the developing world:review of 4539cases from the international Non-Hodgkin lymphoma classification project[J].Haematologica,2016,101(10):1244-1250.
[2] LI YX,FANG H,LIU QF,et al.Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring[J].Blood,2008,112(8):3057-3064.
[3] YANG Y,ZHU Y,CAO JZ,et al.Risk-adapted therapy for earlystage extranodal nasal-type NK/T-cell lymphoma:analysis from a multicenter study[J].Blood,2015,126(12):1424-1432.
[4] WANG L,WANG ZH,CHEN XQ,et al.First-line combination of gemcitabine,oxaliplatin,and L-asparaginase(GELOX)followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma[J].Cancer,2013,119(2):348-355.
[5] DONG LH,ZHANG LJ,WANG WJ,et al.Sequential DICE combined with L-asparaginase chemotherapy followed by involved field radiation in newly diagnosed,stage IE to IIE,nasal and extranodal NK/T-cell lymphoma[J].Leuk Lymphoma,2016,57(7):1600-1606.
[6] RAMAKRISHNAN R,DONAHUE H,GARCIA D,et al.Epstein-Barr virus BART9miRNA modulates LMP1levels and affects growth rate of nasal NK T cell lymphomas[J].PLoS One,2011,6(11):e27271.
[7] KWONG YL,PANG A,LEUNG A,et al.Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol:diagnostic and prognostic significance[J].Leukemia,2014,28(4):865-870.
[8] YAMAGUCHI M,SUZUKI R,OGUCHI M,et al.Treatments and outcomes of patients with extranodal natural killer/T-Cell lymphoma diagnosed between 2000and 2013:a cooperative study in Japan[J].J Clin Oncol,2017,35(1):32-39.
[9] VARGO JA,PATEL A,GLASER SM,et al.The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T-Cell lymphoma,nasal type,in the United States[J].Cancer,2017,123(16):3176-3185.
[10]OGUCHI M,YAMAGUCHI M,SUZUKI R,et al.The multi-institutional retrospective study of radiation therapy for NK/T-cell lymphoma in Japan[J].Radiat Oncol,2016,119(Suppl 1):S309.
[11]LIU X,HUANG E,WANG Y,et al.Dosimetric comparison of helical tomotherapy,VMAT,fixed-field IMRT and 3D-conformal radiotherapy for stageⅠ-Ⅱnasal natural killer T-cell lymphoma[J].Radiat Oncol,2017,12(1):76.
[12]KOOM WS,CHUNG EJ,YANG WI,et al.Angiocentric T-cell and NK/T-cell lymphomas:Radiotherapeutic viewpoints[J].Int J Radiat Oncol Biol Phys,2004,59(4):1127-1137.
[13]LI YX,YAO B,JIN J,et al.Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma[J].J Clin Oncol,2006,24(1):181-189.
[14]HUANG MJ,JIANG Y,LIU WP,et al.Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma,nasal-type in the upper aerodigestive tract[J].Int J Radiat Oncol Biol Phys,2008,70(1):166-174.
[15]JING XM,ZHANG ZH,WU P,et al.Efficacy and tolerance of pegaspargase,gemcitabine and oxaliplatin with sandwiched radiotherapy in the treatment of newly-diagnosed extranodal nature killer(NK)/T cell lymphoma[J].Leuk Res,2016,47:26-31.
[16]WEN JY,LI M,LI X,et al.Efficacy and tolerance of pegaspargase-based chemotherapy in patients with nasal-type extranodal NK/T-cell lymphoma:apilot study[J].Asian Pac J Cancer Prev,2014,15(15):6275-6281.
[17]WANG JH,WANG H,WANG YJ,et al.Analysis of the efficacy and safety of a combined gemcitabine,oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma[J].Oncotarget,2016,7(23):35412-35422.
[18]ZANG J,LI C,LUO SQ,et al.Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK/T cell lymphoma treated with L-asparaginase-containing chemotherapy:a single institution experience[J].Ann Hematol,2015,94(4):583-591.
[19]YAMAGUCHI M,TOBINAI K,OGUCHI M,et al.Concurrent chemoradiotherapy for localized nasal natural killer/T-Cell lymphoma:an updated analysis of the Japan clinical oncology group study JCOG0211[J].J Clin Oncol,2012,30(32):4044-4046.
[20]KIM SJ,YANG DH,KIM JS,et al.Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy,VIDL,for localized nasal extranodal NK/T cell lymphoma:CISL08-01phaseⅡstudy[J].Ann Hematol,2014,93(11):1895-1901.
[21]KWONG YL,KIM SJ,TSE E,et al.Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/IINK/T-cell lymphoma[J].Ann Oncol,2018,29(1):256-263.
[22]SUZUKI R,KWONG YL,MAEDA Y,et al.5-year follow-up of the SMILE phaseⅡstudy for newly-diagnosed stageⅣ,relapsed or refractory extranodal NK/T-cell lymphoma,nasal type[J].Hematol Oncol,2015,33(1):140.
[23]KIM SJ,PARK S,KANG ES,et al.Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stageⅣextranodal natural killer/T-cell lymphoma patients[J].Ann Hematol,2015,94(1):71-78.
[24]JACCARD A,GACHARD N,MARIN B,et al.Efficacy of L-asparaginase with methotrexate and dexamethasone(AspaMetDex regimen)in patients with refractory or relapsing extranodal NK/T-cell lymphoma,aphase 2study[J].Blood,2011,117(6):1834-1839.
[25]YHIM HY,KIM JS,MUN YC,et al.Clinical outcomes and prognostic factors of Up-Front autologous stem cell transplantation in patients with extranodal natural killer/T cell lymphoma[J].Biol Blood Marrow Transplant,2015,21(9):1597-1604.
[26]HUDE I,SASSE S,ENGERT A,et al.The emerging role of immune checkpoint inhibition in malignant lymphoma[J].Haematologica,2017,102(1):30-42.
[27]JO JC,KIM M,CHOI Y,et al.Expression of programmed cell death 1and programmed cell death ligand 1in extranodal NK/Tcell lymphoma,nasal type[J].Ann Hematol,2017,96(1):25-31.
[28]BOLLARD CM,GOTTSCHALK S,TORRANO V,et al.Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins[J].J Clin Oncol,2014,32(8):798-808.
[2] LI YX,FANG H,LIU QF,et al.Clinical features and treatment outcome of nasal-type NK/T-cell lymphoma of Waldeyer ring[J].Blood,2008,112(8):3057-3064.
[3] YANG Y,ZHU Y,CAO JZ,et al.Risk-adapted therapy for earlystage extranodal nasal-type NK/T-cell lymphoma:analysis from a multicenter study[J].Blood,2015,126(12):1424-1432.
[4] WANG L,WANG ZH,CHEN XQ,et al.First-line combination of gemcitabine,oxaliplatin,and L-asparaginase(GELOX)followed by involved-field radiation therapy for patients with stage IE/IIE extranodal natural killer/T-cell lymphoma[J].Cancer,2013,119(2):348-355.
[5] DONG LH,ZHANG LJ,WANG WJ,et al.Sequential DICE combined with L-asparaginase chemotherapy followed by involved field radiation in newly diagnosed,stage IE to IIE,nasal and extranodal NK/T-cell lymphoma[J].Leuk Lymphoma,2016,57(7):1600-1606.
[6] RAMAKRISHNAN R,DONAHUE H,GARCIA D,et al.Epstein-Barr virus BART9miRNA modulates LMP1levels and affects growth rate of nasal NK T cell lymphomas[J].PLoS One,2011,6(11):e27271.
[7] KWONG YL,PANG A,LEUNG A,et al.Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol:diagnostic and prognostic significance[J].Leukemia,2014,28(4):865-870.
[8] YAMAGUCHI M,SUZUKI R,OGUCHI M,et al.Treatments and outcomes of patients with extranodal natural killer/T-Cell lymphoma diagnosed between 2000and 2013:a cooperative study in Japan[J].J Clin Oncol,2017,35(1):32-39.
[9] VARGO JA,PATEL A,GLASER SM,et al.The impact of the omission or inadequate dosing of radiotherapy in extranodal natural killer T-Cell lymphoma,nasal type,in the United States[J].Cancer,2017,123(16):3176-3185.
[10]OGUCHI M,YAMAGUCHI M,SUZUKI R,et al.The multi-institutional retrospective study of radiation therapy for NK/T-cell lymphoma in Japan[J].Radiat Oncol,2016,119(Suppl 1):S309.
[11]LIU X,HUANG E,WANG Y,et al.Dosimetric comparison of helical tomotherapy,VMAT,fixed-field IMRT and 3D-conformal radiotherapy for stageⅠ-Ⅱnasal natural killer T-cell lymphoma[J].Radiat Oncol,2017,12(1):76.
[12]KOOM WS,CHUNG EJ,YANG WI,et al.Angiocentric T-cell and NK/T-cell lymphomas:Radiotherapeutic viewpoints[J].Int J Radiat Oncol Biol Phys,2004,59(4):1127-1137.
[13]LI YX,YAO B,JIN J,et al.Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma[J].J Clin Oncol,2006,24(1):181-189.
[14]HUANG MJ,JIANG Y,LIU WP,et al.Early or up-front radiotherapy improved survival of localized extranodal NK/T-cell lymphoma,nasal-type in the upper aerodigestive tract[J].Int J Radiat Oncol Biol Phys,2008,70(1):166-174.
[15]JING XM,ZHANG ZH,WU P,et al.Efficacy and tolerance of pegaspargase,gemcitabine and oxaliplatin with sandwiched radiotherapy in the treatment of newly-diagnosed extranodal nature killer(NK)/T cell lymphoma[J].Leuk Res,2016,47:26-31.
[16]WEN JY,LI M,LI X,et al.Efficacy and tolerance of pegaspargase-based chemotherapy in patients with nasal-type extranodal NK/T-cell lymphoma:apilot study[J].Asian Pac J Cancer Prev,2014,15(15):6275-6281.
[17]WANG JH,WANG H,WANG YJ,et al.Analysis of the efficacy and safety of a combined gemcitabine,oxaliplatin and pegaspargase regimen for NK/T-cell lymphoma[J].Oncotarget,2016,7(23):35412-35422.
[18]ZANG J,LI C,LUO SQ,et al.Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK/T cell lymphoma treated with L-asparaginase-containing chemotherapy:a single institution experience[J].Ann Hematol,2015,94(4):583-591.
[19]YAMAGUCHI M,TOBINAI K,OGUCHI M,et al.Concurrent chemoradiotherapy for localized nasal natural killer/T-Cell lymphoma:an updated analysis of the Japan clinical oncology group study JCOG0211[J].J Clin Oncol,2012,30(32):4044-4046.
[20]KIM SJ,YANG DH,KIM JS,et al.Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy,VIDL,for localized nasal extranodal NK/T cell lymphoma:CISL08-01phaseⅡstudy[J].Ann Hematol,2014,93(11):1895-1901.
[21]KWONG YL,KIM SJ,TSE E,et al.Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/IINK/T-cell lymphoma[J].Ann Oncol,2018,29(1):256-263.
[22]SUZUKI R,KWONG YL,MAEDA Y,et al.5-year follow-up of the SMILE phaseⅡstudy for newly-diagnosed stageⅣ,relapsed or refractory extranodal NK/T-cell lymphoma,nasal type[J].Hematol Oncol,2015,33(1):140.
[23]KIM SJ,PARK S,KANG ES,et al.Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stageⅣextranodal natural killer/T-cell lymphoma patients[J].Ann Hematol,2015,94(1):71-78.
[24]JACCARD A,GACHARD N,MARIN B,et al.Efficacy of L-asparaginase with methotrexate and dexamethasone(AspaMetDex regimen)in patients with refractory or relapsing extranodal NK/T-cell lymphoma,aphase 2study[J].Blood,2011,117(6):1834-1839.
[25]YHIM HY,KIM JS,MUN YC,et al.Clinical outcomes and prognostic factors of Up-Front autologous stem cell transplantation in patients with extranodal natural killer/T cell lymphoma[J].Biol Blood Marrow Transplant,2015,21(9):1597-1604.
[26]HUDE I,SASSE S,ENGERT A,et al.The emerging role of immune checkpoint inhibition in malignant lymphoma[J].Haematologica,2017,102(1):30-42.
[27]JO JC,KIM M,CHOI Y,et al.Expression of programmed cell death 1and programmed cell death ligand 1in extranodal NK/Tcell lymphoma,nasal type[J].Ann Hematol,2017,96(1):25-31.
[28]BOLLARD CM,GOTTSCHALK S,TORRANO V,et al.Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins[J].J Clin Oncol,2014,32(8):798-808.